{
"id":"mk19_bb_cv_s4",
"subspecialtyId":"cv",
"title":"Heart Failure",
"jsonContent":{
"type":"section",
"id":"mk19_bb_cv_s4",
"title":{
"__html":"Heart Failure"
},
"titleNode":{
"type":"section-title",
"hlId":"6ff5ed",
"children":[
"Heart Failure"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_cv_s4_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"9a6ca8",
"children":[
{
"type":"abbreviation",
"title":"heart failure with reduced ejection fraction",
"children":[
"HFrEF"
]
},
" is defined by an ",
{
"type":"abbreviation",
"title":"left ventricular ejection fraction",
"children":[
"LVEF"
]
},
" of ≤40%. Common causes include ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"coronary artery disease",
"children":[
"CAD"
]
},
","
]
},
" hypertension, diabetes, and valvular heart disease. ",
{
"type":"abbreviation",
"title":"heart failure with preserved ejection fraction",
"children":[
"HFpEF"
]
},
" is commonly defined by an LVEF of ≥50%. Hypertension is the most common cause."
]
},
{
"type":"p",
"hlId":"1d32ae",
"children":[
"Patients with HFrEF often have dilated ventricles, and patients with HFpEF have normal systolic contraction and normal-sized ventricles or concentric hypertrophy."
]
},
{
"type":"p",
"hlId":"e94f8a",
"children":[
"Symptoms are the same for HFrEF and HFpEF. Symptoms and signs that increase the likelihood of ",
{
"type":"abbreviation",
"title":"heart failure",
"children":[
"HF"
]
},
" include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"bd922d",
"children":[
"paroxysmal nocturnal dyspnea (>2-fold likelihood)"
]
},
" ",
{
"type":"list-item",
"hlId":"f40f4b",
"children":[
"an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
},
" (11-fold likelihood)"
]
},
" "
]
},
{
"type":"p",
"hlId":"81108d",
"children":[
"The likelihood of HF is decreased 50% by:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"73b4ea",
"children":[
"absence of dyspnea on exertion"
]
},
" ",
{
"type":"list-item",
"hlId":"fb8f91",
"children":[
"absence of crackles on pulmonary auscultation"
]
},
" "
]
},
{
"type":"p",
"hlId":"0c6db7",
"children":[
"Disease classification systems are part of the diagnosis and can help guide treatment decisions."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_cv_s4_inline_t1"
],
"forceOpen":true
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s4_2",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"7bb04e",
"children":[
" ",
{
"type":"alert",
"children":[
"A ",
{
"type":"abbreviation",
"title":"B-type natriuretic peptide",
"children":[
"BNP"
]
},
" level >400 pg/mL is compatible with HF, and a level <100 pg/mL argues against HF as a cause of acute dyspnea."
]
},
" "
]
},
{
"type":"p",
"hlId":"478e86",
"children":[
"The ",
{
"type":"abbreviation",
"title":"electrocardiogram",
"children":[
"ECG"
]
},
" may show a previous ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"myocardial infarction",
"children":[
"MI"
]
},
","
]
},
" ventricular hypertrophy, arrhythmias, or conduction abnormalities. Chest x-rays may show cardiomegaly, pulmonary edema, or pleural effusion. Echocardiography will estimate ",
{
"type":"abbreviation",
"title":"ejection fraction",
"children":[
"EF"
]
},
" and may detect valvular heart disease, ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"hypertrophic cardiomyopathy",
"children":[
"HCM"
]
},
","
]
},
" and regional wall abnormalities suggesting CAD."
]
},
{
"type":"p",
"hlId":"250567",
"children":[
"Other studies include stress testing or coronary angiography to detect myocardial ischemia, depending on the patient's symptoms and risk factors, and measurement of serum ",
{
"type":"abbreviation",
"title":"thyroid-stimulating hormone",
"children":[
"TSH"
]
},
" level."
]
},
{
"type":"p",
"hlId":"2818f8",
"children":[
{
"type":"abbreviation",
"title":"cardiac magnetic resonance (imaging)",
"children":[
"CMR"
]
},
" imaging can assess for myocarditis and infiltrative processes, such as hemochromatosis, sarcoidosis, and amyloidosis. Routine CMR imaging should be used only when clinical suspicion warrants."
]
},
{
"type":"p",
"hlId":"3316b2",
"children":[
"Endomyocardial biopsy is rarely indicated but can assist in the diagnosis of giant cell myocarditis and sarcoidosis."
]
},
{
"type":"p",
"hlId":"e30873",
"children":[
"A sleep study should be performed on symptomatic patients with ",
{
"type":"abbreviation",
"title":"New York Heart Association",
"children":[
"NYHA"
]
},
" class II-IV HFrEF and excessive daytime sleepiness. Obstructive and central sleep apneas can be treated with ",
{
"type":"abbreviation",
"title":"continuous positive airway pressure",
"children":[
"CPAP"
]
},
" if conditions persist despite guideline-directed medical therapy."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"2d39ad",
"children":[
"Routine testing for unusual causes of HF, including hemochromatosis, multiple myeloma, amyloidosis, and myocarditis, should not be performed."
]
},
" ",
{
"type":"list-item",
"hlId":"80869a",
"children":[
"Don't order serial BNPs in ambulatory patients to monitor HF or guide therapy."
]
},
" ",
{
"type":"list-item",
"hlId":"c623db",
"children":[
"Kidney failure, older age, and female sex all increase BNP; obesity reduces BNP."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s4_3",
"title":{
"__html":"Treatment of HFrEF"
},
"titleNode":{
"type":"section-title",
"hlId":"be0198",
"children":[
"Treatment of HFrEF"
]
},
"children":[
{
"type":"p",
"hlId":"4cb9a2",
"children":[
"For making treatment decisions, NYHA functional classification provides guidance."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_cv_s4_inline_t2"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"8190e4",
"children":[
"Lower ",
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
},
" to <130/80 mm Hg; encourage weight loss and smoking cessation; and offer vaccination for COVID-19, pneumonia, and influenza."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"3e613d",
"children":[
"Do not begin β-blocker therapy in patients with decompensated HF."
]
},
" ",
{
"type":"list-item",
"hlId":"ffab77",
"children":[
"Continuous IV infusion of furosemide provides no advantage vs. bolus therapy in decompensated HF."
]
},
" ",
{
"type":"list-item",
"hlId":"49cbac",
"children":[
"Do not prescribe or continue ",
{
"type":"abbreviation",
"title":"nonsteroidal anti-inflammatory drugs",
"children":[
"NSAIDs"
]
},
" or thiazolidinediones because they worsen HF."
]
},
" ",
{
"type":"list-item",
"hlId":"4027d2",
"children":[
"Nondihydropyridine calcium channel blockers (diltiazem or verapamil) may be harmful to patients with HFrEF."
]
},
" ",
{
"type":"list-item",
"hlId":"495d2b",
"children":[
"Do not implant ",
{
"type":"abbreviation",
"title":"implantable cardioverter defibrillator",
"children":[
"ICD"
]
},
" until guideline-directed medical therapy has been administered for 3 months (or 40 days after MI) to assess potential recovery of LVEF."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s4_4",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"db0526",
"class":"test",
"children":[
"A 64-year-old woman with previously stable HF now has increasing orthopnea. Medications are lisinopril 10 mg/d and furosemide 20 mg/d. BP is 140/68 mm Hg, and ",
{
"type":"abbreviation",
"title":"hazard ratio; heart rate",
"children":[
"HR"
]
},
" is 102/min. Pulmonary crackles and increased ",
{
"type":"abbreviation",
"title":"jugular venous distention",
"children":[
"JVD"
]
},
" are present."
]
},
{
"type":"p",
"hlId":"9e3d87",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For treatment, increase the furosemide and lisinopril dosages and add a β-blocker when the patient is stable."
]
},
{
"type":"p",
"hlId":"18236a",
"children":[
"Strategies to prevent readmission include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"a13c41",
"children":[
"treatment of reversible causes of HF exacerbation"
]
},
" ",
{
"type":"list-item",
"hlId":"2eda40",
"children":[
"euvolemia achieved with diuresis"
]
},
" ",
{
"type":"list-item",
"hlId":"b33992",
"children":[
"medication reconciliation"
]
},
" ",
{
"type":"list-item",
"hlId":"3fd793",
"children":[
"discharge with medications that reduce mortality and morbidity"
]
},
" ",
{
"type":"list-item",
"hlId":"8f4433",
"children":[
"patient education on HF physiology"
]
},
" ",
{
"type":"list-item",
"hlId":"6f515d",
"children":[
"home nurse follow-up (or phone call within 48 h) soon after discharge"
]
},
" ",
{
"type":"list-item",
"hlId":"1f7d22",
"children":[
"follow-up appointment (within 7 days)"
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_cv_s4_5",
"title":{
"__html":"Follow-up"
},
"titleNode":{
"type":"section-title",
"hlId":"b9c20d",
"children":[
"Follow-up"
]
},
"children":[
{
"type":"p",
"hlId":"0867ad",
"children":[
"In patients with chronic HF who experience a change in clinical symptoms, follow-up echocardiography is recommended."
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_cv_s4_inline_t1":{
"id":"mk19_bb_cv_s4_inline_t1",
"number":1,
"bookId":"cv",
"title":{
"__html":"Study Table: Classification Schemes of Heart Failure That Guide Therapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6c08d4",
"children":[
"Study Table: Classification Schemes of Heart Failure That Guide Therapy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e9095",
"class":"col hd l",
"children":[
{
"type":"abbreviation",
"title":"New York Heart Association",
"children":[
"NYHA"
]
},
" Functional Classification"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf3b99",
"class":"col hd l",
"children":[
{
"type":"abbreviation",
"title":"American College of Cardiology",
"children":[
"ACC"
]
},
"/",
{
"type":"abbreviation",
"title":"American Heart Association",
"children":[
"AHA"
]
},
" Stages of Heart Failure"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b916a",
"class":"cell txt l",
"children":[
"I: No limitations of physical activity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"534eeb",
"class":"cell txt l",
"children":[
"A: At risk for heart failure but without structural heart changes (e.g., patients with diabetes mellitus, coronary artery disease, hypertension, vascular disease)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"942a67",
"class":"cell txt l",
"children":[
"II: Slight limitation of physical activity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"045dcb",
"class":"cell txt l",
"children":[
"B: Structural heart disease (e.g., reduced ejection fraction, left ventricular hypertrophy, chamber enlargement) but without heart failure symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d56d5",
"class":"cell txt l",
"children":[
"III: Marked limitation of physical activity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61aa45",
"class":"cell txt l",
"children":[
"C: Structural heart disease with current or prior heart failure symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f763b",
"class":"cell txt l",
"children":[
"IV: Unable to carry on any physical activity without symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5dd0c2",
"class":"cell txt l",
"children":[
"D: Refractory heart failure requiring advanced intervention (e.g., biventricular pacemaker, left ventricular assist device, transplantation)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_cv_s4_inline_t2":{
"id":"mk19_bb_cv_s4_inline_t2",
"number":2,
"bookId":"cv",
"title":{
"__html":"Study Table: Treatment of HFrEF"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e7bf51",
"children":[
"Study Table: Treatment of HFrEF"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8b7674",
"class":"col hd l",
"children":[
"Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b7d4",
"class":"cell txt l",
"children":[
{
"type":"abbreviation",
"title":"angiotensin-converting enzyme",
"children":[
"ACE"
]
},
" inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9755ee",
"class":"cell txt l",
"children":[
"For all NYHA stages of HF to reduce mortality"
]
},
" ",
{
"type":"p",
"hlId":"e4368d",
"class":"cell txt l",
"children":[
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"angiotensin receptor blocker",
"children":[
"ARB"
]
},
"s"
]
},
" are acceptable if ACE inhibitor cannot be tolerated"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02a1c2",
"class":"cell txt l",
"children":[
"Valsartan-sacubitril"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e1345",
"class":"cell txt l",
"children":[
"Initiate or substitute for an ACE inhibitor or ARB in HFrEF (NYHA class II-IV and EF <40%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"207f45",
"class":"cell txt l",
"children":[
"Hydralazine plus nitrates"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4f4b0",
"class":"cell txt l",
"children":[
"Given in addition to standard therapy for NYHA class III-IV and EF <40% in select patients (low output syndrome, hypertension) to reduce mortality"
]
},
" ",
{
"type":"p",
"hlId":"4ddf4a",
"class":"cell txt l",
"children":[
"For patients who cannot tolerate ACE inhibitors or ARBs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60f643",
"class":"cell txt l",
"children":[
"β-Blockers (only metoprolol succinate, carvedilol, and bisoprolol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25b295",
"class":"cell txt l",
"children":[
"For NYHA class I-IV to reduce mortality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5799e6",
"class":"cell txt l",
"children":[
"Aldosterone antagonist (spironolactone or eplerenone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3637a7",
"class":"cell txt l",
"children":[
"For NYHA class III-IV HF to reduce mortality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d04e7c",
"class":"cell txt l",
"children":[
"Digitalis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3989a",
"class":"cell txt l",
"children":[
"Used predominantly in patients who continue to experience symptoms despite guideline-directed medical therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"808737",
"class":"cell txt l",
"children":[
"Diuretics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"111e42",
"class":"cell txt l",
"children":[
"Given to improve symptoms of volume overload"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07d276",
"class":"cell txt l",
"children":[
"Ivabradine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"580b41",
"class":"cell txt l",
"children":[
"EF ≤35% who are in sinus rhythm with a heart rate ≥70/min despite maximal β-blocker therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c87f1",
"class":"cell txt l",
"children":[
"Sodium-glucose cotransporter-2 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8b98d",
"class":"cell txt l",
"children":[
"To reduce the risk of cardiovascular events and HF hospitalization regardless of the presence of type 2 diabetes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbb533",
"class":"cell txt l",
"children":[
"Iron therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93aaa3",
"class":"cell txt l",
"children":[
"Treatment of iron deficiency anemia improves functional capacity and quality of life"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d021",
"class":"cell txt l",
"children":[
"ICD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61a9a5",
"class":"cell txt l",
"children":[
"For ischemic and nonischemic cardiomyopathy in patients with an EF ≤35% and NYHA functional class II-III or with an EF ≤30% and NYHA functional class I to improve survival"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64502a",
"class":"cell txt l",
"children":[
"Cardiac resynchronization therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c4c5f",
"class":"cell txt l",
"children":[
"For NYHA class II-IV, LVEF ≤35%, ",
{
"type":"abbreviation",
"title":"left bundle branch block",
"children":[
"LBBB"
]
},
" with QRS duration >150 ms, and sinus rhythm to improve LVEF and reduce symptoms and mortality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b104f",
"class":"cell txt l",
"children":[
"Exercise training"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"287f18",
"class":"cell txt l",
"children":[
"Recommended in all patients with newly diagnosed HF"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}